Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a new revision label, updating from v3.3.1 to v3.3.2, a maintenance/version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision label in the page footer changed from v3.2.0 to v3.3.1; no changes to study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedDeleted the recurring government funding status notice that warned users information may not be up to date and that inquiries could be delayed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check36 days agoChange DetectedRemoved Lung cancer and MedlinePlus Genetics from the related topics section on the study page.SummaryDifference0.2%

- Check43 days agoChange DetectedAdded related topics to the page: Lung cancer and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check71 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference4%

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.